Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.
复制标题
通过聚合酶链反应测定双脱氧核苷治疗后血浆人类免疫缺陷病毒核糖核酸的减少。
DOI：
10.1172/jci115494
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Merigan,TC
中科院分区：
文献类型：
--
作者：
Holodniy,M;Katzenstein,DA;Israelski,DM;Merigan,TC
用聚合酶链式反应检测抗病毒治疗后血浆中无细胞HIV RNA的含量。从血浆中提取RNA，反转录为cDNA，聚合酶链式反应扩增，酶联亲和分析吸光度定量。72名HIV抗体阳性的受试者采集了一份血浆样本。39名当时未接受抗逆转录病毒治疗的患者的血浆HIV RNA平均拷贝数为每200微升690+/-360(平均+/-扫描电子显微镜)，而33名接受至少3个月的齐多夫定治疗的患者的平均拷贝数为134+/-219(P<0.05)。另有27例HIV抗体阳性患者在开始双脱氧核苷治疗前和治疗后1个月分别采集两份血浆样本。血浆HIVRNA拷贝数从540+/-175下降到77+/-35(P<0.05)。最后，其中9名受试者在开始治疗前获得了两个基线样本，并在治疗开始后1个月和2个月获得了两个治疗后样本。治疗1mo后，血浆RNA平均拷贝数由794+/-274降至<40(低于敏感度下限)，治疗2mo后仍维持抑制状态。这些结果表明，基因扩增可以用来检测和定量双脱氧核苷治疗后血浆HIV RNA的变化。血浆HIV聚合酶链式反应可能是监测抗病毒治疗的更敏感的标志物，特别是在p24抗原检测或定量血浆培养阴性的无症状患者。
Cell-free HIV RNA in plasma was detected and quantitated after antiviral therapy by the polymerase chain reaction. RNA was extracted from plasma, reverse transcribed to cDNA, amplified by polymerase chain reaction, and quantitated by absorbance based on an enzyme-linked affinity assay. 72 HIV antibody-positive subjects had one plasma sample taken. 39 who were not receiving antiretroviral therapy at the time had a mean plasma HIV RNA copy number of 690 +/- 360 (mean +/- SEM) per 200 microliters of plasma, while 33 subjects who had been receiving zidovudine therapy for a minimum of 3 mo had a mean copy number of 134 +/- 219 (P less than 0.05). 27 additional HIV antibody-positive patients had two plasma samples taken before and 1 mo after initiating dideoxynucleoside therapy. Plasma HIV RNA copy number fell from 540 +/- 175 to 77 +/- 35 (P less than 0.05). Finally, nine of these subjects had two baseline samples obtained before initiating therapy and two posttreatment samples 1 and 2 mo after therapy was begun. Mean plasma RNA copy number declined from 794 +/- 274 to less than 40 (below the lower limit of sensitivity) after 1 mo of therapy, with suppression maintained after 2 mo of therapy. These results suggest that gene amplification can be used to detect and quantitate changes in plasma HIV RNA after dideoxynucleoside therapy. Plasma HIV polymerase chain reaction may be a more sensitive marker to monitor antiviral therapy, particularly in asymptomatic patients where measurement of p24 antigen or quantitative plasma cultures are negative.